Entrada Therapeutics (TRDA) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
210.8M
Operating Income
47.0M
22.30%
Net Income
65.6M
31.13%
Balance Sheet Metrics
Total Assets
526.3M
Total Liabilities
97.6M
Shareholders Equity
428.7M
Debt to Equity
0.23
Cash Flow Metrics
Operating Cash Flow
-25.5M
Free Cash Flow
-44.7M
Revenue & Profitability Trend
Entrada Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 210.8M | 129.0M | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 163.8M | 132.2M | 97.2M | 51.1M | 26.7M |
| Operating Income | 47.0M | -3.2M | -97.2M | -51.1M | -26.7M |
| Pre-tax Income | 66.5M | 12.1M | -94.6M | -51.2M | -26.5M |
| Income Tax | 859.0K | 18.7M | 0 | - | - |
| Net Income | 65.6M | -6.7M | -94.6M | -51.2M | -26.5M |
| EPS (Diluted) | - | -$0.20 | -$3.02 | -$8.16 | -$1.30 |
Income Statement Trend
Entrada Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 440.0M | 369.8M | 209.9M | 298.7M | 39.9M |
| Non-Current Assets | 86.3M | 99.4M | 42.2M | 7.1M | 3.6M |
| Total Assets | 526.3M | 469.2M | 252.1M | 305.8M | 43.5M |
| Liabilities | |||||
| Current Liabilities | 39.5M | 158.8M | 22.0M | 6.7M | 3.4M |
| Non-Current Liabilities | 58.2M | 68.0M | 17.5M | 396.0K | 81.7M |
| Total Liabilities | 97.6M | 226.8M | 39.5M | 7.1M | 85.0M |
| Equity | |||||
| Total Shareholders Equity | 428.7M | 242.4M | 212.6M | 298.7M | -41.5M |
Balance Sheet Composition
Entrada Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 65.6M | -6.7M | -94.6M | -51.2M | -26.5M |
| Operating Cash Flow | -25.5M | 129.1M | -81.7M | -48.2M | -25.9M |
| Investing Activities | |||||
| Capital Expenditures | -3.2M | -5.6M | -2.9M | -4.6M | -2.3M |
| Investing Cash Flow | -27.8M | -138.4M | -148.6M | -4.6M | -2.3M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 99.6M | 19.4M | 0 | 306.5M | 49.8M |
| Free Cash Flow | -44.7M | 134.2M | -96.7M | -55.4M | -27.9M |
Cash Flow Trend
Entrada Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.34
Forward P/E
-2.27
Price to Book
0.60
Price to Sales
1.58
PEG Ratio
-2.27
Profitability Ratios
Profit Margin
14.39%
Operating Margin
-105.99%
Return on Equity
7.22%
Return on Assets
0.51%
Financial Health
Current Ratio
21.88
Debt to Equity
13.66
Beta
-0.06
Per Share Data
EPS (TTM)
$0.58
Book Value per Share
$11.84
Revenue per Share
$4.39
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| trda | 271.7M | 12.34 | 0.60 | 7.22% | 14.39% | 13.66 |
| Vertex | 124.2B | 32.82 | 7.53 | -5.64% | -8.91% | 10.00 |
| Regeneron | 59.1B | 13.92 | 1.97 | 15.96% | 31.94% | 9.20 |
| Cg Oncology | 2.0B | -19.18 | 2.81 | -16.58% | 0.00% | 0.15 |
| Belite Bio | 1.9B | -54.37 | 12.07 | -33.43% | 0.00% | 0.00 |
| Disc Medicine | 1.9B | 4.99 | 2.93 | -23.34% | 0.00% | 4.64 |
Financial data is updated regularly. All figures are in the company's reporting currency.